Introduction

▼
Each year an episode of acute bronchitis is estimated to aff ect about 5 % of the general population [ 1 ] . The majority of these patients seek medical attention, and this accounts for millions of offi ce visits per year. The major reason for seeking care is for symptom relief particularly during the fi rst week of illness. Respiratory viruses appear to be the most common cause of acute bronchitis (predominantly rhinovirus, infl uenza or parainfl uenza virus, respiratory syncytial virus, coronavirus or adenovirus) [ 1 , 2 ] although the responsible germ is identifi ed in clinical practice only rarely. Bacterial infections are thought to occur in fewer than 10 % of all cases [ 1 , 2 ] ; the most common bacteria in otherwise healthy individuals include Mycoplasma pneumoniae, Chlamydia pneumoniae and Bordetella pertussis [ 3 ] . According to the ACCP (American College of Chest Physicians) there is no causative treatment available and consequently at least one on-treatment effi cacy evaluation (Myrtol ® : 196; Placebo: 202) . The mean change in coughing fi ts from D01 (baseline) to D07-D09 (after about one week treatment) was 62.1 % (95 % CI: 57.6-66.6 %) and 49.8 % (95 % CI: 44.6-55.0 %) for treatment with Myrtol ® and placebo, respectively (p < 0.0001). With Myrtol ® , the median time to 50 % reduction in coughing fi ts was statistically signifi cantly shorter and there were more patients without day-time coughing fi ts; there also were statistically signifi cantly less day-time coughing fi ts, less diffi culty coughing up, less sleep disturbance due to night-time coughing; with Myrtol ® there was less symptomatic impairment (composite bronchitis severity score and subscores) and signifi cant more patients had a clinically satisfying response to the investigational treatment. Both treatments were generally well tolerated.
Conclusions:
Myrtol ® is statistically significantly superior to placebo in treating acute bronchitis.
cultural Practice and Good Manufacturing Practice. This guarantees a consistent high quality. The active ingredient of GeloMyrtol ® forte is produced out of plants of the Myrtaceae family and the Rutaceae family. The Myrtaceae oils are obtained by steam distillation whereas the Rutaceae oils are obtained by expression of the peels. The oils are then further processed and purifi ed by subsequent distillation steps. Myrtol is approved for the treatment of acute and chronic bronchitis and sinusitis in many European and non-European countries for several decades. Clinically, Myrtol has already been shown to be effi cacious in the treatment of acute bronchitis, this also in comparison to active control medication like ambroxol and antibiotics [ 4 ] . For conditions such as acute bronchitis with a spontaneous recovery, a verifi cation and confi rmation relative to placebo is considered to be relevant and important. In this way the present study exemplifi es continuing eff orts to investigate and document the drug's therapeutic effi cacy above and beyond the already existing documentation in patients with acute bronchitis.
Methods
▼
Ethical considerations
The study was performed in accordance with the Declaration of Helsinki and the Notes for Guidance on Good Clinical Practice. The study protocol, patient information and informed consent form were reviewed and approved by the competent central ethic committee of the Federal State of Bavaria which is competent for the country co-ordinating investigator in Germany, the local ethics committees of all investigators and the German Federal Institute for Drugs and Medical Devices (BfArM). Participation in the study was voluntary. Only subjects who were willing and able to provide informed consent were eligible.
Design
The study was conducted in a multi-centre, randomised, placebo-controlled, double-blind, parallel-group fashion. Eligible patients with acute bronchitis were randomly assigned 1:1 to a 2-week treatment with 4 daily doses of either 300 mg Myrtol or matched placebo capsules. Preclinically, Myrtol was shown to enhance mucociliary clearance due to muco-secretomotoric actions and additionally, to have anti-infl ammatory and anti-oxidant properties. Based on these actions and properties, Myrtol could be hypothesised to be of therapeutic value in the treatment of acute bronchitis by liquefying otherwise viscous secretions and facilitating their expectoration, reducing cough frequency and reducing coughing discomfort, while also avoiding impaction of secretions and preventing bacterial superinfection. This hypothesis has been tested and confi rmed over the past decades for several secretomotoric/-mucolytic medications. In all such investigations, it is of prime importance to demonstrate whether and how such medication facilitates and accelerates the otherwise spontaneous recovery of the disease (as observed under placebo).
Since acute bronchitis is a condition characterised by a spontaneous regression [ 5 , 6 ] , patients assigned to treatment with placebo were not exposed to undue risk or inconvenience. The value of medication in the present study lies in a relevant reduction of symptoms and a more rapid and more complete recovery relative to the course under placebo. There were no relevant on-study changes in the trial design. 
Time schedule
The study lasted 2 weeks ± 2 days. It comprised 4 visits: visit V1: screening for eligibility, enrolment and randomisation -start of investigational treatment -dispensing of diary and medication for the fi rst treatment week; visit V2 (study day D07 ± 1): evaluation after 1 week of treatment; evaluation of effi cacy, tolerability, and compliance -dispensing of diary and medication for the second treatment week; visit V3 (study day D10 ± 2): evaluation after 10 days of treatment; evaluation of effi cacy, tolerability, and compliance -continuation of the investigational treatment; visit V4 (study day D14 ± 2): end-of-trial evaluation. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 
Study Medication
Medication supplies of GeloMyrtol ® forte and matched placebo capsules were provided by the sponsor. Individualised medication boxes solely identifi ed by a randomly assigned treatment ID-number were dispensed. For each patient, medication boxes were distributed by treatment week. Care was taken that each patient was only treated with medication in accordance with his/her randomly set treatment assignment number.
Blinding
The investigators and the patients were blinded with regard to the nature of the medication assigned to each trial participant by using matched medication supplies for active and placebo medication (re. identical blisters, outer package, labelling, capsule size and outer appearance of the medication packs). Supplies were only identifi ed by the respective treatment assignment number in accordance with the randomisation plan. Trial data were only unblinded after closure of the database.
Randomisation
Patients were assigned at random 1:1 to treatment with either Myrtol or matched placebo. The randomisation plan was generated by the data centre by means of RANCODE-Software by IDV. Randomization was carried out in blocks of 4 by trial site. Individual medication supplies were only identifi ed by treatment assignment number and consisted of either Myrtol or placebo in accordance with the randomisation plan. At visit V1, eligible patients were assigned by the investigator to their subject/treatment number in order of entrance to the study starting with the lowest number fi rst, and were then treated with the corresponding medication throughout.
Treatments
The fi rst dose was applied at the end of V1; otherwise, the patients took the medications themselves at home. Each intake was recorded in a diary. Patient compliance (drug accountability and documentation in the diary) was checked by the investigator at each visit (V2, V3, V4). According to the approved dosage recommendations of GeloMyrtol ® forte for acute bronchitis the patients were instructed to take 4 capsules per day for 2 weeks: 1 capsule in the morning (30 min before breakfast), 1 capsule midday (30 min before lunch), 1 capsule in the evening (30 min before dinner), and 1 capsule late in the evening at bedtime [ 7 ] . The capsules were to be taken with suffi cient cold water.
Study criteria and methods -effi cacy
The evaluation of effi cacy was based a) on the patients' daily records in weekly diaries and b) the investigators' assessment of the patients' condition at the scheduled visits. The validation of the used parameters frequency of day-time coughing fi ts and Bronchitis Severity Score is based on several clinical studies on acute bronchitis [ 8 -12 ] in which they were defi ned as important tools for the evaluation of the effi cacy of the study medication. Furthermore, the signifi cance and value of these 2 parameters is confi rmed by the guideline for acute and chronic cough of the German Society of Pneumology [ 13 ] . ▶ Frequency of day-time coughing fi ts (defi ned as a single coughing event of 3 or more consecutive coughs) counted using a manual counter from waking up to bedtime and recorded daily in the diary at bedtime; the number of coughing fi ts on day D01 was set as baseline.
▶ Response to treatment: at each on-/post-treatment visit, response to treatment was scored by the investigator by means of a verbal rating scale (VRS: 0 = symptoms healed [cured], 1 = symptoms improved compared to baseline, 2 = symptoms unchanged compared to baseline, 3 = symptoms deteriorated compared to baseline); patients with scores 0 or 1 were defi ned as "responders"; patients with scores 2 or score 3 were defi ned as "non-responders". ▶ Bronchitis Severity Score (BSS): at each visit, the investigator scored the intensity for each lead sign/symptom (cough, sputum, rales/rhonchi, chest pain during coughing, and dyspnoea) using a 5-point VRS (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe). The BSS was calculated as the sum of these scores; in order to be eligible, the patients had to have a baseline BSS of at least 5/20 points. ▶ Diffi culty to cough-up mucus during the day: at baseline (V1; CRF-record) and in the evening of D01-D13 (diary records), the presence ("yes"/ "no") of day-time and night-time cough and the diffi culty of expectoration on coughing -if presentwas scored (VRS: 0 = no problem to cough up mucus, 1 = mild problems to cough up mucus, 2 = coughing-up mucus is impaired, 3 = coughing-up mucus is very impaired). ▶ Sleep disturbance due to coughing at night: at baseline (V1; CRF-record) and in the morning of D01-D14 (diary records), the patient rated his/her sleep disturbance during the preceding night (VRS: 0 = "I cannot remember waking up due to coughing", 1 = "I slept well although I can remember coughing during the night", 2 = I woke up due to at least one severe coughing fi t, but I fell asleep again", 3 = "I hardly slept because of many severe coughing fi ts"). ▶ Work incapacitation: at the last scheduled visit (V4), the investigator was to score the patients' work incapacitation to acute bronchitis (total number of days until Day D14). ▶ Diary data: coughing fi ts during the day, disturbance of sleep by cough, type of cough (sputum consistence) and general wellbeing as recorded daily by the patient on categorised verbal rating scales (VRS). ▶ Visit data: at each visit, the investigator recorded body temperature, fi ndings of lung auscultation ("normal" or "abnormal"; if abnormal, the fi ndings were to be specifi ed acc. to predefi ned categories) and the 1 s Forced Expiratory Volume (FEV 1 ); additionally, at each visit, the absence/presence of bronchial hyperreactivity (characterised by coughing when exposed to cold/change of temperature, during exercise and/ or when exposed to noxious substances), acute rhinitis, sore throat, diffi culty swallowing, hoarseness, headache, pain in limbs and joints, fatigue, others (with specifi cation) were recorded.
Study criteria and methods -safety and tolerability
Safety and tolerability were evaluated with regard to the following ▶ Safety: the presence of adverse events (AE) and changes in general well-being was recorded throughout, at each visit and at the telephone contact on Day 3. ▶ Vital signs: at each visit, the patients' blood pressure (mmHg) and pulse rate (bpm) was measured using an automated oscillometric device after 5 min rest each time using the same arm. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 
Statistical analysis -Criteria for comparison of the investigational treatments
▶ Primary criterion: ratio of the mean frequency of day-time coughing fi ts on days D07-D09 to the baseline frequency on D01. ▶ Secondary criteria: for the daily day-time coughing fi ts, difficulty of coughing-up, sleep disturbance due to night-time coughing, and impairment of general wellbeing, the course of the data was summarised by the trapezoidal area under the course of the respective data (AUD) from baseline (D01) to the respective endpoint.
Statistical analysis -Datasets
▶ SEP (Safety Evaluable Population): all patients who took the assigned trial medication at least once and for whom at least one post-/on-treatment safety evaluation was available. ▶ FAS (Full Analysis Set): all patients who took the assigned trial medication at least once and for whom at least one post-/ on-treatment effi cacy evaluation was available. ▶ PP (Per-Protocol Set for sensitivity analysis): FAS-patients without relevant protocol deviation(s) and with effi cacy data (number of coughing fi ts) for at least D07, D08, and D09; patients who terminated the study prematurely due to insuffi cient effi cacy (incl. elevated body temperature or evidence of pneumonia) were not excluded from the PP.
Statistical analysis -Sample size estimates
The size of the study sample had been set a priori assuming a 50 % reduction of the mean frequency of day-time coughing fi ts on days D07-D09 from baseline for the placebo group and an additional 10 % reduction under active treatment. Assuming the standard deviation of the baseline-normalised frequency of coughing fi ts to be 0.35 and setting the type-I error rate to 2.5 % 1-sided and the statistical power to 80 % yielded an estimate of 194 patients per treatment group using the t-test approach (program StudySize version 1.09). Assuming a rate of approximately 3 % non-evaluable patients, 200 patients had been scheduled to be enrolled in each of the 2 treatment groups (total N = 400).
Statistical analysis -Interim analysis
After completion of 262 patients, a protocol-defi ned blinded interim analysis was carried-out in order to verify whether the estimate of the standard deviation of the baseline-normalised frequency of coughing fi ts had been appropriate. The estimate was confi rmed and the sample size was kept as originally planned.
Statistical analysis -Handling of missing information
In the FAS dataset, completely missing diaries were not imputed by any procedure. If only baseline data were available, these data were not used for imputation of proceeding values (no "Baseline-value" carried forward). Otherwise, missing data were imputed according to a Last Observation Carried Forward [LOCF] method that was fi xed at the Blinded Review Meeting and Valid Statement depending on the criterion and the kind of data loss.
In the PP dataset, LOCF was only carried-out for those missing data in the CRF that resulted from non-effi cacy of the investigational trial medication (premature study termination because of lack of effi cacy incl. high fever or evidence of pneumonia).
Statistical analysis -Treatment contrasts
Baseline values were considered to be the most important confounder with an impact on the study results; accordingly, baseline adjustment was performed either by defi ning variables relative to baseline (e. g. for the primary endpoint) or by adjusting baseline eff ects by the statistical method afterwards (e. g. ANOVA or ANCOVA). As indicated, treatments were contrasted by analysis of variance with 'Treatment' as fi xed eff ect and 'Centre' as a random eff ect; in the event that the ANOVA-residuals revealed signifi cant non-normality, a Wilcoxon-Mann-Whitney test stratifi ed by centre was performed instead (Van Elteren test). For the time to 50 % reduction in coughing fi ts, the treatments were contrasted by means of a Log-Rank test.
Results
▼
Patient disposition
The study was carried out in 29 Fig. 1 . In the Myrtol group, the most common reasons for premature study discontinuation were withdrawal of consent and lost-to-follow-up (4/16 dropouts each). Other reasons were AEs (n = 3) and insuffi cient effi cacy (n = 3). In the placebo group, dropout reasons were insuffi cient effi cacy (7 from 21 discontinuations), AEs (n = 6) and withdrawal of consent (n = 4).
Demography
The FAS of 398 patients consisted of 217 [54. 
Baseline features -Diagnosis and disease severity
All patients had an acute bronchitis of recent onset ( ≤ 2 days). At study start, all patients suff ered from cough, of which the intensity was severe in 142 patients (35.7 %), and even very severe in very poor and 86 % of all patients had pathological auscultation fi ndings. There were no relevant diff erences between the study groups with regard to the disease intensity at baseline. 
Baseline features -Co-morbidity
Baseline features -Co-medication
Compliance
Based on the diary records including Day D09, patients' mean adherence to study medication was almost 100 % in both treatment groups (Myrtol: 62.0-100.0 %, mean 98.1 ± 5.3 %; placebo 73.0-100 %, mean 98.2 ± 4.5 %). 5 patients were excluded due to low treatment adherence ( = protocol violation).
Effi cacy
Treatment with Myrtol proved consistently superior to Placebo with regard to primary and secondary outcome parameters: ▶ There was a signifi cantly lower mean frequency of day-time coughing fi ts for days D07-D09 from (expressed as ratio of the baseline frequency on Day D01) for treatment with Myrtol: this corresponds to a mean change in coughing fi ts of 62. Table 2 ) and Fig. 1 Study subject disposition: number of subjects enrolled, number of subjects treated, number of subjects who discontinued from the trial prematurely, and number of subjects who completed the trial regularly after 14 days of investigational treatment (visit V4). Note: all screened subjects were enrolled. ▶ there was less sleep disturbance due to night-time coughing (FAS, p = 0.0007; • ▶ Table 2 ).
Additionally, Myrtol proved superior to Placebo also with regard to responder and non-responder rates: ▶ Already in the second treatment week more than 90 % of the patients of the Myrtol-group could be considered "responders" (healed/cured or improved), distinctly and statistically signifi cantly more than for the Placebo treatment (Day D07: Also, treatment with Myrtol proved superior to Placebo also in terms of the Bronchitis Severity Score (BSS): ▶ The mean BSS has been about the same for both treatment groups at baseline; at each on-treatment visit, the mean BSS was distinctly lower in the Myrtol-group than in the patients treated with Placebo. Accordingly, the mean changes in BSS from baseline were larger at each on-treatment visit in the patients treated with Myrtol than in the patients treated with Placebo; at all visits, the treatment diff erence was statistically signifi cant (p < 0.0001; • ▶ Fig. 6 ).
▶ For the BSS-Subscores (cough, sputum, rales/ rhonchi, chest pain on coughing, and dyspnoea) a similarly benefi cial eff ect of the Myrtol-treatment relative to the Placebo-treatment was seen; on Day D10, the mean changes from baseline for all subscores were statistically signifi cantly lower for the Myrtol-group than for the Placebo-group ( • ▶ Fig. 7 ) ; on Day D14, this also applied except for 'chest pain on coughing' and 'dyspnoea', for which there was little diff erence between the 2 treatments ( • ▶ Fig. 8 ).
Safety and tolerability
39 AEs were reported (32/413 = 7.7 %): 21 AEs in 16/202 patients of the Myrtol-group (7.9 %) and 18 AEs in 16/211 patients of the placebo-group (7.6 %). In the Myrtol group, the investigators classifi ed 10 AEs in 8 patients as at least possibly drug related. In the placebo group, 2 AEs in 2 patients had a reasonable causal relationship to the test medication. Most of these adverse drug reactions (ADR) were of mild-to-moderate intensity including eructation, nausea or mild diarrhoea in the Myrtol-group and moderate abdominal pain in the placebo-group. All events resolved without sequelae within the protocoldefi ned observation and follow-up time. In the Myrtol-group, 5 ADRs led to premature discontinuation of 3 patients from the trial. In the placebo-group, 2 ADRs led to premature discontinuation of 2 patients. The present study was conducted with Myrtol and its new coating as test medication. The incidence rate of gastro-intestinal disorders was 0.035. In a previous randomised, placebo and actively controlled, double-blind clinical trial Myrtol was administered with its old coating, resulting in a higher incidence rate of gastro-intestinal disorders of 0.083. This corresponds to a relative risk reduction (RRR) of 58 %.
Discussion
▼
Acute bronchitis is mostly of viral origin but later bacterial superinfect infection might occur [ 14 ] ; nevertheless, it is still quite often treated with antibiotics [ 1 , 5 , 6 , 14 -16 ] . The natural course of an acute bronchitis mainly in terms of cough generally lasts 4 weeks on average until complete recovery [ 17 ] . Cough is the most commonly observed symptom of acute bronchitis beginning within 2 days of initial infection in up to 85 % of all cases. Most patients have a cough for less than 2 weeks although many are still coughing after 2 weeks, and a few cough for up to 6-8 weeks or longer [ 1 , 18 ] . The diagnosis of acute bronchitis is mainly clinical, with cough as main symptom [ 19 ] . Microscopic examination or culture of sputum in the healthy adult with acute bronchitis generally is not helpful. Since most cases of acute bronchitis are caused by viruses, cultures are usually negative or exhibit normal respiratory fl ora [ 20 ] . Moreover, it recommend to limit the testing of the pathogens only to special cases, e. g. in case of already existing bronchopulmonary diseases and in hospitalized patients [ 20 -22 ] . The benefi t of antibiotics is small [ 23 , 24 ] in relation to the risk of promoting bacterial resistance [ 17 , 25 -27 ] . In spite of many eff orts little change in the prescribing habits in this indication has yet been reached. This often is explained by the patients' pressure and expectations [ 28 -30 ] . These are likely to result from the substantial symptomatic discomfort that acute bronchitis causes in spite of its otherwise benign natural course and from the concern about bacterial (super-) infection. This is particularly the case when coughing is pronounced and regresses more slowly. Therefore, there is an urgent need for an eff ective treatment alternative. Tussisedatives may help the patient symptomatically, but they carry the risk a) of suppressing the body's protective mechanism for airway clearance and this might delay healing, and b) in promoting drug dependency when using opioid derivatives. Mucolytic i. e., secretolytic and secretomotoric agents such as in Myrtol may therefore be better suited, but generally their therapeutic positioning needs to be endorsed by more and better evidence of their effi cacy and safety. Myrtol has been shown to be effi cacious in the treatment of lower respiratory tract diseases like acute [ 4 ] and chronic [ 31 ] bronchitis as well of upper respiratory tract diseases like acute [ 32 ] and chronic sinusitis [ 33 ] in well-designed, GCP-compliant, prospective, randomised, double-blind, Placebo-and activelycontrolled, parallel-group trials. This is explained by its secretomucolytic, secretomotoric, and mucociliary clearance enhancing properties [ 33 -40 ] ; further pharmacological properties contribute as well, anti-infl ammatory [ 41 -43 ] and anti-oxidant actions [ 44 , 45 ] , in particular; furthermore bacteriostatic properties were demonstrated in in-vitro studies [ 33 , 46 ] . The large therapeutic margin and excellent safety of Myrtol is supported by a full panel of toxicological studies required by pertinent European guidelines [ 47 ] . Currently the scientifi c documentation of Myrtol contains around 100 preclinical and 27 clinical studies [ 33 ] . The fi ndings of the present study are in agreement with an earlier randomised, double-blind, placebo-controlled study, which also evidenced the superiority of Myrtol 4 times daily over placebo [ 4 ] . In this earlier trial, the non-responder rate was much higher in the placebo group (20.9 % after 1 week treatment) when compared with Myrtol (5.3 %). Even after 2 weeks of treatment the effi cacy ratio remained about the same (p: 0.001). After 2 weeks, 50 % of the Myrtol patients but only about 30 % in the placebo group where cough free during the day. Also, the overall effi cacy was rated as very good or good after one treatment week in 86 % of the patients of the Myrtol group, but only for 47 % of the placebo patients. The present study confi rms these fi ndings. Since GeloMyrtol ® forte is commonly used in the country where this study was conducted, the participating physicians and patients were to be expected to be well familiar with this medication. For this reason, the true nature of the investigational medication was not disclosed. Nevertheless the study has some limitations. Here a strict distinction between common cold, bacterial or viral induced acute bronchitis was not promoted. On the other side acute bronchitis is normally diagnosed clinically and as mentioned above most patients suff ering from acute bronchitis are not tested. Myrtol has many additional characteristics besides containing a compound with mere mucolytic characteristics. Begrow et al. [ 39 ] and Kwok et al. [ 40 ] demonstrated that Myrtol in pharmacologically doses stimulates ciliary beat frequency and thus increases mucociliary clearance in the lower as well as in the upper respiratory tract in vivo. It could further be demonstrated that Myrtol inhibits pro-infl ammatory eff ects of activated alveolar macrophages derived from patients with chronic obstructive pulmonary disease (COPD) [ 41 ] . All these eff ects not only promotes the mucociliary clearance in the human bronchi but also reduces the exaggerated infl ammation and therefore promotes an enhanced elimination of bacteria including the clearance of pseudomonas aeruginosa as demonstrated by Cao et al. [ 37 ] in COPD-rat model. Therefore it can presumed, that the positive eff ect we found in our trial is the result of these drug characteristics. We further could demonstrate that Myrtol was well tolerated and that there was no signifi cant diff erence compared with placebo. Interestingly, for Myrtol with the new coating there is a 58 % reduction in the risk of gastro-intestinal disorders compared to Myrtol with the previous coating [ 4 ] .
